
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc is positioned for a positive financial outlook due to anticipated revenue growth from its Signatera test, which has shown impressive quarterly gains with a 54% year-over-year increase in molecular residual disease volumes. The company's strong performance in the most recent quarter included an approximately $80 million revenue beat and a significant raise in its 2025 revenue guidance by $160 million. Furthermore, Natera's efforts to expand reimbursement coverage for additional cancer types could enhance average selling prices and bolster operating cash flow, contributing to overall financial strength.
Bears say
Natera Inc faces significant challenges that contribute to a negative outlook, primarily due to anticipated erosion of margins stemming from pricing reductions as more commercial payors become involved and the addressable market expands to encompass average-risk patients. Furthermore, potential setbacks related to regulatory issues, reimbursement complications, or delays in product launches could adversely impact financial performance and lead to a decline in stock value. The company's expansion efforts in international markets also face headwinds from the lack of compelling data and possible obstacles related to pricing and reimbursement, complicating the overall growth trajectory.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares